JP2015522542A - 非小細胞肺癌を処置するための方法 - Google Patents

非小細胞肺癌を処置するための方法 Download PDF

Info

Publication number
JP2015522542A
JP2015522542A JP2015512895A JP2015512895A JP2015522542A JP 2015522542 A JP2015522542 A JP 2015522542A JP 2015512895 A JP2015512895 A JP 2015512895A JP 2015512895 A JP2015512895 A JP 2015512895A JP 2015522542 A JP2015522542 A JP 2015522542A
Authority
JP
Japan
Prior art keywords
clusterin
lung cancer
small cell
cell lung
nucleotides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015512895A
Other languages
English (en)
Japanese (ja)
Inventor
ドゥクシン、チェン
テスラー、ショーシ
Original Assignee
テバ ファーマシューティカル インダストリーズ リミティド
テバ ファーマシューティカル インダストリーズ リミティド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by テバ ファーマシューティカル インダストリーズ リミティド, テバ ファーマシューティカル インダストリーズ リミティド filed Critical テバ ファーマシューティカル インダストリーズ リミティド
Publication of JP2015522542A publication Critical patent/JP2015522542A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5752—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the lungs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2015512895A 2012-05-18 2013-05-17 非小細胞肺癌を処置するための方法 Pending JP2015522542A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261649092P 2012-05-18 2012-05-18
US61/649,092 2012-05-18
PCT/US2013/041652 WO2013173757A1 (en) 2012-05-18 2013-05-17 Method for treating non-small cell lung cancer

Publications (1)

Publication Number Publication Date
JP2015522542A true JP2015522542A (ja) 2015-08-06

Family

ID=49581824

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015512895A Pending JP2015522542A (ja) 2012-05-18 2013-05-17 非小細胞肺癌を処置するための方法

Country Status (17)

Country Link
US (1) US20130310440A1 (enExample)
EP (1) EP2849761A1 (enExample)
JP (1) JP2015522542A (enExample)
KR (1) KR20150024843A (enExample)
CN (1) CN104684564A (enExample)
AR (1) AR091090A1 (enExample)
AU (1) AU2013262589A1 (enExample)
BR (1) BR112014028787A2 (enExample)
CA (1) CA2874092A1 (enExample)
EA (1) EA201492148A1 (enExample)
IL (1) IL235459A0 (enExample)
IN (1) IN2014DN10390A (enExample)
PH (1) PH12014502569A1 (enExample)
SG (1) SG11201407649RA (enExample)
TW (1) TW201402132A (enExample)
UY (1) UY34812A (enExample)
WO (1) WO2013173757A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE385237T1 (de) 1999-02-26 2008-02-15 Univ British Columbia Antisense-therapie für trpm-2
US7569551B2 (en) 2000-02-25 2009-08-04 The University Of British Columbia Chemo- and radiation-sensitization of cancer by antisense TRPM-2 oligodeoxynucleotides
PT3581105T (pt) 2010-05-08 2022-10-19 Univ California Dispositivo para detecção precoce de úlceras por rastreio da humidade subepidermal
MX2013010524A (es) 2011-03-15 2013-12-06 Univ British Columbia Combinacion de oligonucleotido anti-clusterina con inhibidor hsp90 para el tratamiento de cancer de prostata.
CN104473973B (zh) * 2014-12-19 2015-08-05 山东创新药物研发有限公司 一株戈氏梭菌驯化株的应用
US10182740B2 (en) 2015-04-24 2019-01-22 Bruin Biometrics, Llc Apparatus and methods for determining damaged tissue using sub-epidermal moisture measurements
CN109195606A (zh) * 2016-05-13 2019-01-11 国鼎生物科技股份有限公司 用于治疗晚期非小细胞肺癌的方法和组合物
CN109890272B (zh) 2017-02-03 2022-05-17 布鲁恩生物有限责任公司 组织存活力的测量
JP6900477B2 (ja) 2017-02-03 2021-07-07 ブルーイン、バイオメトリクス、リミテッド、ライアビリティー、カンパニーＢｒｕｉｎ Ｂｉｏｍｅｔｒｉｃｓ， Ｌｌｃ コンパートメント症候群を評価するための装置、およびコンパートメント症候群を検出するためのコンピュータ可読媒体
CN118177725A (zh) 2017-02-03 2024-06-14 布鲁恩医疗创新有限责任公司 糖尿病足溃疡易感性的测量
KR20240159026A (ko) 2017-11-16 2024-11-05 브루인 바이오메트릭스, 엘엘씨 복수의 케어 환경에 걸쳐 케어의 연속성 제공
US20190211044A1 (en) * 2018-01-05 2019-07-11 LifeUnit Inc. Adjuvant Chemicals that Prevent Drug Tolerance and Persister Formation by Bacteria
US11471094B2 (en) 2018-02-09 2022-10-18 Bruin Biometrics, Llc Detection of tissue damage
SI3861601T1 (sl) 2018-10-11 2024-05-31 Bruin Biometrics, Llc Naprava z elementom za enkratno uporabo
US11642075B2 (en) 2021-02-03 2023-05-09 Bruin Biometrics, Llc Methods of treating deep and early-stage pressure induced tissue damage

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6900187B2 (en) * 1999-02-26 2005-05-31 The University Of British Columbia TRPM-2 antisense therapy using an oligonucleotide having 2′-O-(2-methoxy)ethyl modifications
US20060024692A1 (en) * 2002-09-30 2006-02-02 Oncotherapy Science, Inc. Method for diagnosing non-small cell lung cancers
WO2005094899A1 (en) * 2004-04-02 2005-10-13 The University Of British Columbia Clusterin antisense therapy for treatment of cancer
MX2010014228A (es) * 2008-06-18 2011-03-29 Abbott Laboratories Star Metodos y productos de diagnostico del p/gf-1 acompañante.
AU2012257487A1 (en) * 2011-05-19 2014-01-16 Teva Pharmaceutical Industries Ltd. Method for treating non-small cell lung cancer

Also Published As

Publication number Publication date
EP2849761A1 (en) 2015-03-25
TW201402132A (zh) 2014-01-16
KR20150024843A (ko) 2015-03-09
UY34812A (es) 2013-12-31
CA2874092A1 (en) 2013-11-21
AU2013262589A1 (en) 2015-01-22
WO2013173757A1 (en) 2013-11-21
PH12014502569A1 (en) 2015-01-21
AR091090A1 (es) 2014-12-30
EA201492148A1 (ru) 2015-04-30
WO2013173757A8 (en) 2015-04-30
IN2014DN10390A (enExample) 2015-08-14
US20130310440A1 (en) 2013-11-21
BR112014028787A2 (pt) 2017-06-27
SG11201407649RA (en) 2014-12-30
CN104684564A (zh) 2015-06-03
IL235459A0 (en) 2014-12-31

Similar Documents

Publication Publication Date Title
JP2014520081A (ja) 非小細胞肺癌を処置するための方法
US20130310440A1 (en) Method for treating non-small cell lung cancer
Nakajima et al. Multicenter phase I/II study of nivolumab combined with paclitaxel plus ramucirumab as second-line treatment in patients with advanced gastric cancer
Yuan et al. Camrelizumab combined with apatinib in patients with first-line platinum-resistant or PD-1 inhibitor resistant recurrent/metastatic nasopharyngeal carcinoma: a single-arm, phase 2 trial
Dotan et al. Phase Ib study of Wnt inhibitor ipafricept with gemcitabine and nab-paclitaxel in patients with previously untreated stage IV pancreatic cancer
Haura et al. A phase II study of PD-0325901, an oral MEK inhibitor, in previously treated patients with advanced non–small cell lung cancer
Diep et al. Synergistic effect between erlotinib and MEK inhibitors in KRAS wild-type human pancreatic cancer cells
JP6242213B2 (ja) 薬物送達および治療用薬剤の有効性を向上させる方法
JP5926724B2 (ja) がんを処置する方法
Laquente et al. Antiangiogenic effect of gemcitabine following metronomic administration in a pancreas cancer model
KR20160132496A (ko) 초분자 조합 치료제
KR20200014298A (ko) Her2 양성 암의 치료
CN110072550A (zh) 用于治疗脑癌的组合疗法
CN104039343A (zh) 基于he4治疗恶性疾病
JP6587142B2 (ja) マイクロｒｎａからなるがん治療剤
Gao et al. High glucose-upregulated PD-L1 expression through RAS signaling-driven downregulation of PTRH1 leads to suppression of T cell cytotoxic function in tumor environment
CN107750165A (zh) 借助塞里班土单抗的组合治疗
JPWO2014126233A6 (ja) マイクロｒｎａの測定方法、並びに、がん治療剤及びこれを含有するがん治療のための医薬組成物
Ardalan et al. A phase I study of 5-fluorouracil/leucovorin and arsenic trioxide for patients with refractory/relapsed colorectal carcinoma
Powell et al. Phase II study of topotecan and bevacizumab in advanced, refractory non–small-cell lung cancer
Croxtall et al. Trastuzumab: in HER2-positive metastatic gastric cancer
Piha-Paul et al. Phase I dose-escalation trial of AMXT 1501 dicaprate plus difluoromethylornithine: a dual-agent approach targeting immunosuppressive polyamine metabolism
Chi et al. Phase I dose-finding study of sorafenib with FOLFOX4 as first-line treatment in patients with unresectable locally advanced or metastatic gastric cancer
Waddell Evaluation of the role of anti-EGFR therapy in advanced gastro-oesophageal malignancy and determination of prognostic and predictive markers in this disease
Mantrana et al. A phase 1b study of CBP501, a novel immunogenic cell death inducer, combined with cisplatin and nivolumab in patients with advanced solid tumors